Unknown

Dataset Information

Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis.


ABSTRACT: Context:Denosumab is a potent antiresorptive agent that reduces fractures in postmenopausal women with osteoporosis. Objective:Determine effects of up to 10 years of denosumab on bone histology, remodeling, and matrix mineralization characteristics. Design and Setting:International, multicenter, randomized, double-blind trial [Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM)] with a long-term open-label extension. Patients:Postmenopausal women with osteoporosis (92 women in FREEDOM, 46 in extension) who provided iliac bone biopsies, including 11 who provided biopsies at multiple time points. Interventions:FREEDOM subjects were randomized 1:1 to subcutaneous denosumab 60 mg or placebo every 6 months for 3 years. Long-term extension subjects continued recei

SUBMITTER: Dempster DW 

PROVIDER: S-EPMC6037073 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature